Jordan T.

Gladman
1739 Sugar Maple Court Charlottesville VA 22903 (614) 284-7461 gladman.12@buckeyemail.osu.edu
www.linkedin.com/in/jordangladman

Dynamic, results-oriented professional with over 10 years of experience in academic and industrial life
science, biomedical research, and project management generating high-quality results. Accomplished
presenter and communicator with numerous peer-review publications and presentations at international
events seeking a position in an organization utilizing team work, analytical, and leadership skills.

Postdoctoral Research Associate University of Virginia, Charlottesville VA

2010-Present
Managed projects with multiple personal to complete research on in a competitive timeline.
Interacted with both scientists and individuals diagnosed with myotonic dystrophy resulting in
identification of community needs and encouraging collaborative engagement.
Skills Used: Team science, Scientific writing, Protocol development, Project management
Graduate Research Associate
The Ohio State University, Columbus, OH
2004-2010
Analyzed data to identify conserved mRNA splicing elements between mouse and man leading to
the generation of a spinal muscular atrophy mouse model.
Wrote a NRSA Fellowship that was awarded by the NIH/NIGMS (F31-GM605623-01A1) securing
research funding and reducing laboratory personal costs.
Skills Used: Biomedical driven laboratory research, Grant writing, Data-gathering
Intern
Battelle Memorial Institute, Columbus, OH
2001-2004

Ph.D.
The Ohio State University, Columbus, OH
Integrated Biomedical Sciences: Integrating science across multiple biomedical disciplines
B.S. Molecular Biology
Ohio Northern University, Ada, OH

2010
2004

Board of Directors, Secretary

Thrive Healthcare, Charlottesville, VA
2013-Present
Lead committees aimed at implementing our strategic plan while safeguarding financial and
fiduciary obligations ensuring continued and improved services.
Skills Used: Communication, Strategic planning, Non-profit organization management
Enrichment Program Assistant
Thomas Jefferson Foundation, Charlottesville, VA 2011-Present
Worked as part of a team to organize programs and events for 100+ visitors to Monticello.
Skills Used: Client satisfaction, Customer survive, Hospitality
Postdoctoral Research Day Committee, Travel Grant Advisory Committee, Hiring Committee

Analytical thinker
Literature review and analysis
Statistical methodology

Synthesizing and summarizing data

In vivo and In vitro biomedical and life
science research

Health in Numbers: Quantitative Methods in Clinical & Public Health Research. PH207x edX/Harvard
Experience with study design, confidence intervals and hypothesis testing, power and sample size.
Toxicology for Industrial and Regulatory Scientists Course, American College of Toxicology, May 2014
Evaluated preclinical pharmacological and toxicological IND and NDA regulatory submissions.

Jordan Gladman

Page 2

1. Gladman JT, Mandal M, Srinivasan V, Mahadevan MS Age of Onset of RNA Toxicity Influences
Phenotypic Severity: Evidence from an Inducible Mouse Model of Myotonic Dystrophy (DM1).
International Myotonic Dystrophy Consortium 9, San Sebastian, Spain, October 9 October 12
2013. Selected Oral Presentation
2. Gladman JT, Yadava RS, Mandal M, Yu Q, Mahadevan MS Elucidating the Role of NKX2-5
Expression in Skeletal Muscle. International Myotonic Dystrophy Consortium 8, Clearwater Beach,
Florida, November 30 December 3 2011. Selected Oral Presentation
3. Gladman JT, Bebee TW, and Chandler DS. Elucidating the complex pre-mRNA splicing regulation of
the SMN genes using evolutionarily conserved sequence comparison. 15th Annual Meeting of the
RNA Society, Seattle, Washington, June 22 - June 26, 2010. Poster Presentation
4. Gladman JT, Bebee TW, and Chandler DS. Generation of an In Vitro System to Evaluate SMN2
Corrective Splicing Therapies. The Gordon Conference on The Biology of Post-Transcriptional Gene
Regulation, June 30 - July 4, 2008, Colby College, Maine. Poster Presentation
5. Gladman JT and Chandler DS. SMN2 Silent Mutation Knock-In: A New Model for Spinal Muscular
Atrophy. Pediatric Academic Societies Annual 2006 Meeting, San Francisco, CA, May 2006. Poster
Presentation

1. Gladman JT, Yadava RS, Mandal M, Yu Q, Kim YK, Mahadevan MS. NKX2-5, a Modifier of Skeletal
Muscle Pathology due to RNA Toxicity. Hum Mol Genet. 24(1), Pages 251-64 (2015). doi:
10.1093/hmg/ddu443
2. Yadava RS, Foff EP, Gladman JT, Kim YK, Bhatt KS, Thornton CA, Zheng TS, Mahadevan MS.
TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy. Hum Mol Genet
(2014)
3. Gladman JT, Mandal M, Srinivasan V, Mahadevan MS. Age of Onset of RNA Toxicity Influences
Phenotypic Severity: Evidence from an Inducible Mouse Model of Myotonic Dystrophy (DM1). PLOS
One. 8(9) (2013 September 5). doi: 10.1371/journal.pone.0072907
4. Rehman S, Gladman JT, Periasamy A, Sun Y, Mahadevan MS. Development of an AP-FRET Based
Analysis for Characterizing RNA-Protein Interactions in Myotonic Dystrophy (DM1). PLoS One. 9(4)
(2014 April 29). doi: 10.1371/journal.pone.0095957
5. Jacob AG, O'Brien D, Singh RK, Comiskey DF Jr, Littleton RM, Mohammad F, Gladman JT, Widmann
MC, Jeyaraj SC, Bolinger C, Anderson JR, Barkauskas DA, Boris-Lawrie K, Chandler DS. Stressinduced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing
network in pediatric rhabdomyosarcoma. Neoplasia. 15(9), Pages 1049-63 (2013).
6. Gladman JT, Bebee TW, Edwards C, Wang X, Sahenk X, Rich MM, Chandler DS. A humanized Smn
gene containing the SMN2 nucleotide alteration in exon 7 mimics SMN2 splicing and the SMA disease
phenotype. Hum Mol Genet. 19(21), Pages 4239-52 (2010). doi: 10.1093/hmg/ddq343
7. Gladman JT and Chandler DS. Intron 7 conserved sequence elements regulate the splicing of the
SMN gene. Hum Genet. 126(6), Page 833 (2009). doi: 10.1007/s00439-009-0733-7